Profil
Richard Colvin formerly worked at Novartis, Inc., as Executive Director-Translational Medicine from 2014 to 2018 and bluebird bio, Inc., as VP & Head-Severe Genetic Diseases Clinical R&D from 2020 to 2021.
Dr. Colvin received his undergraduate degree from Cornell University and doctorate degree from Duke University School of Medicine.
Ehemalige bekannte Positionen von Richard Colvin
| Unternehmen | Position | Ende |
|---|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco, CA. | Corporate Officer/Principal | 01.10.2018 |
| GENETIX BIOTHERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Richard Colvin
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco, CA. | Health Technology |
bluebird bio, Inc.
bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University School of Medicine
Duke University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















